TMED10P2

Across TCGA pan-cancer cohorts, TMED10P2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of TMED10P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TMED10P2 RNA is repressed in tumor relative to normal tissue. In most cancer types TMED10P2 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

KIRC, LUSC, and THCA are the cancer types where TMED10P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMED10P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.518	<.001	12	view →
LUSC	Female	II,III,IV	−2.540	<.001	9	view →
THCA	All	III,IV	−0.388	<.001	9	view →
LUAD	Female	III,IV	−1.785	<.001	7	view →
KIRP	Male	All	−1.013	<.001	6	view →
HNSC	All	All	+0.260	.003	4	view →
STAD	All	II,III,IV	−0.140	.005	4	view →
PAAD	Female	All	−1.724	.014	2	view →
PRAD	All	All	−0.471	.002	2	view →
COAD	Female	III,IV	−0.214	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

TMED10P2–KIRC

Open the KIRC breakdown →